|Bid||32.94 x 2000|
|Day's Range||33.74 - 33.82|
|52 Week Range||33.52 - 38.86|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.63%|
The Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) of the FDA, has invited PharmaMar to participate in this ODAC, giving a presentation to provide background information on Zepsyre™, positive clinical data obtained from phases I and II, in which a good tolerance and a good safety profile were observed, and to assess the potential role of this drug in pediatric cancers and hematological disorders. Zepsyre™ (PM1183), PharmaMar´s investigational drug, is one of the three products chosen by ODAC.
When the dust finally settled on Amazon.com, Inc. (NASDAQ: AMZN )’s historic $13.7 billion buyout bid for Whole Foods Market, Inc. (NASDAQ: WFM ) on Friday, Whole Foods stock was up 29.1 percent on the ...
MADRID , June 16, 2017 /PRNewswire/ -- PharmaMar ( MCE: PHM ) has announced that PM1183 (lurbinectedin), its third molecule of marine origin and analogue of Yondelis ® , will receive the trade name of ...